NERV
Minerva Neurosciences, Inc.
$4.77
-0.15 (-3.05%)
At close · Jul 7
Market Cap
$222.23M
Shares
46,588,709
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.77
Open$4.92
Day$4.59–4.95
52W$1.59–12.46
Avg vol 30d283K
Short int1.1M · 2.4% float · 10.6d
Short vol84%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
−8%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
29%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−4%
trailing
6-month return
+10%
trailing
YTD return
+19%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Flat
1 of 44 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.40% of float · ▲ +13.8% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
44 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
EPS growth
−18347%
Y/Y
Free cash flow
$-13.5M
Balance sheet
$82.3M
net cash
Quant / Vol
risk profile
Volatility
172%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
9.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
−8%
Bearish
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
29%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Flat
1 of 44 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.40% of float · ▲ +13.8% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
44 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $5 · 29%
52-wk high $12
vs 200-day avg -1%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NERV
this stock
Minerva Neurosciences, Inc.
|
$222.23M | +18.7% | +0.0% | — | 2.4% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NERV | -12.2% | -3.8% | +10.4% | -14.1% | +18.7% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -13.1% | -5.2% | +2.9% | -14.2% | +9.0% |